Treatment of axial spondyloarthritis patients with biologic disease-modifying anti-rheumatic drugs in 2022 - data from the Romanian Registry of Rheumatic Diseases
Objective. The objective of this cross-sectional study was to analyze data available in the Romanian Registry of Rheumatic Diseases (RRBR) in 2022 for axial spondyloarthritis (axSpA) patients treated with biologic disease modifying anti-rheumatic drugs (bDMARDs). Methods. From the RRBR electronic da...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Amaltea Medical Publishing House
2023-12-01
|
| Series: | Romanian Journal of Rheumatology |
| Subjects: | |
| Online Access: | https://rjr.com.ro/articles/2023.4/RJR_2023_4_Art-04.pdf |
| _version_ | 1797257915762999296 |
|---|---|
| author | Laura Muntean Razvan Ionescu Corina Mogosan Maria-Magdalena Tamas Claudiu C. Popescu Elena Rezus Razvan-Constantin Ionitescu Ana Maria Ramazan Andrei Eugen Martin Catalin Codreanu |
| author_facet | Laura Muntean Razvan Ionescu Corina Mogosan Maria-Magdalena Tamas Claudiu C. Popescu Elena Rezus Razvan-Constantin Ionitescu Ana Maria Ramazan Andrei Eugen Martin Catalin Codreanu |
| author_sort | Laura Muntean |
| collection | DOAJ |
| description | Objective. The objective of this cross-sectional study was to analyze data available in the Romanian Registry of Rheumatic Diseases (RRBR) in 2022 for axial spondyloarthritis (axSpA) patients treated with biologic disease modifying anti-rheumatic drugs (bDMARDs). Methods. From the RRBR electronic database were collected multiple variables, including patient’s demographic and clinical characteristics, treatment characteristics, patterns of treatment use (initiations, continuations, switching, tapering), and treatment efficacy data of axSpA patients, from 1 January 2022 to 31 December 2022. Results. In 2022, a total of 4315 axSpA patients were registered in the RRBR database: 70% were men, 48.4 years mean age, 13.3 years mean disease duration, 90% with radiographic axSpA, with high prevalence of extra-musculoskeletal manifestations and cardiovascular comorbidities. Most patients (88%) were treated with a tumor necrosis factor inhibitor (TNFi), usually in monotherapy. The most frequently prescribed bDMARDs were adalimumab (36%), etanercept (32%) and secukinumab (12%). The uptake of biosimilars reached one third of patients from molecules with available biosimilars in 2022. Most patients had a good clinical response, irrespective of clinical form, disease duration, type of medication or line of treatment. Medication switching was needed in 10% of patients, the main reason for switching was secondary loss of efficacy. Medication tapering was implemented in 11% of patients, and it was successful in 90% of cases. Conclusion. Data from RRBR provide a valuable real-world view of clinical practice at the national level regarding biologic treatment of axSpA patients. |
| first_indexed | 2024-03-07T23:02:35Z |
| format | Article |
| id | doaj.art-e596e648f6714bed88bc3bdf41fe27fd |
| institution | Directory Open Access Journal |
| issn | 1843-0791 2069-6086 |
| language | English |
| last_indexed | 2024-04-24T22:45:14Z |
| publishDate | 2023-12-01 |
| publisher | Amaltea Medical Publishing House |
| record_format | Article |
| series | Romanian Journal of Rheumatology |
| spelling | doaj.art-e596e648f6714bed88bc3bdf41fe27fd2024-03-18T13:25:17ZengAmaltea Medical Publishing HouseRomanian Journal of Rheumatology1843-07912069-60862023-12-0132415316010.37897/RJR.2023.4.4Treatment of axial spondyloarthritis patients with biologic disease-modifying anti-rheumatic drugs in 2022 - data from the Romanian Registry of Rheumatic DiseasesLaura Muntean0Razvan Ionescu1Corina Mogosan2Maria-Magdalena Tamas3Claudiu C. Popescu4Elena Rezus5Razvan-Constantin Ionitescu6Ana Maria Ramazan7Andrei Eugen Martin8Catalin Codreanu9Rheumatology Clinic, Cluj-Napoca, Romania; “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania3rd Internal Medicine Department, Colentina University Hospital, Bucharest, Romania; “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; “Dr. Ion Stoia” Clinical Center for Rheumatic Diseases, Bucharest, RomaniaRheumatology Clinic, Cluj-Napoca, Romania; “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; “Dr. Ion Stoia” Clinical Center for Rheumatic Diseases, Bucharest, RomaniaClinical Recovery Hospital, Iasi, Romania“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania“Sf. Apostol Andrei” Clinical Emergency Hospital, Constanta, Romania“Dr. I. Cantacuzino” Clinical Hospital, Bucharest, Romania“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; “Dr. Ion Stoia” Clinical Center for Rheumatic Diseases, Bucharest, RomaniaObjective. The objective of this cross-sectional study was to analyze data available in the Romanian Registry of Rheumatic Diseases (RRBR) in 2022 for axial spondyloarthritis (axSpA) patients treated with biologic disease modifying anti-rheumatic drugs (bDMARDs). Methods. From the RRBR electronic database were collected multiple variables, including patient’s demographic and clinical characteristics, treatment characteristics, patterns of treatment use (initiations, continuations, switching, tapering), and treatment efficacy data of axSpA patients, from 1 January 2022 to 31 December 2022. Results. In 2022, a total of 4315 axSpA patients were registered in the RRBR database: 70% were men, 48.4 years mean age, 13.3 years mean disease duration, 90% with radiographic axSpA, with high prevalence of extra-musculoskeletal manifestations and cardiovascular comorbidities. Most patients (88%) were treated with a tumor necrosis factor inhibitor (TNFi), usually in monotherapy. The most frequently prescribed bDMARDs were adalimumab (36%), etanercept (32%) and secukinumab (12%). The uptake of biosimilars reached one third of patients from molecules with available biosimilars in 2022. Most patients had a good clinical response, irrespective of clinical form, disease duration, type of medication or line of treatment. Medication switching was needed in 10% of patients, the main reason for switching was secondary loss of efficacy. Medication tapering was implemented in 11% of patients, and it was successful in 90% of cases. Conclusion. Data from RRBR provide a valuable real-world view of clinical practice at the national level regarding biologic treatment of axSpA patients.https://rjr.com.ro/articles/2023.4/RJR_2023_4_Art-04.pdfaxial spondyloarthritisbiologicsromanian registry of rheumatic diseases |
| spellingShingle | Laura Muntean Razvan Ionescu Corina Mogosan Maria-Magdalena Tamas Claudiu C. Popescu Elena Rezus Razvan-Constantin Ionitescu Ana Maria Ramazan Andrei Eugen Martin Catalin Codreanu Treatment of axial spondyloarthritis patients with biologic disease-modifying anti-rheumatic drugs in 2022 - data from the Romanian Registry of Rheumatic Diseases Romanian Journal of Rheumatology axial spondyloarthritis biologics romanian registry of rheumatic diseases |
| title | Treatment of axial spondyloarthritis patients with biologic disease-modifying anti-rheumatic drugs in 2022 - data from the Romanian Registry of Rheumatic Diseases |
| title_full | Treatment of axial spondyloarthritis patients with biologic disease-modifying anti-rheumatic drugs in 2022 - data from the Romanian Registry of Rheumatic Diseases |
| title_fullStr | Treatment of axial spondyloarthritis patients with biologic disease-modifying anti-rheumatic drugs in 2022 - data from the Romanian Registry of Rheumatic Diseases |
| title_full_unstemmed | Treatment of axial spondyloarthritis patients with biologic disease-modifying anti-rheumatic drugs in 2022 - data from the Romanian Registry of Rheumatic Diseases |
| title_short | Treatment of axial spondyloarthritis patients with biologic disease-modifying anti-rheumatic drugs in 2022 - data from the Romanian Registry of Rheumatic Diseases |
| title_sort | treatment of axial spondyloarthritis patients with biologic disease modifying anti rheumatic drugs in 2022 data from the romanian registry of rheumatic diseases |
| topic | axial spondyloarthritis biologics romanian registry of rheumatic diseases |
| url | https://rjr.com.ro/articles/2023.4/RJR_2023_4_Art-04.pdf |
| work_keys_str_mv | AT lauramuntean treatmentofaxialspondyloarthritispatientswithbiologicdiseasemodifyingantirheumaticdrugsin2022datafromtheromanianregistryofrheumaticdiseases AT razvanionescu treatmentofaxialspondyloarthritispatientswithbiologicdiseasemodifyingantirheumaticdrugsin2022datafromtheromanianregistryofrheumaticdiseases AT corinamogosan treatmentofaxialspondyloarthritispatientswithbiologicdiseasemodifyingantirheumaticdrugsin2022datafromtheromanianregistryofrheumaticdiseases AT mariamagdalenatamas treatmentofaxialspondyloarthritispatientswithbiologicdiseasemodifyingantirheumaticdrugsin2022datafromtheromanianregistryofrheumaticdiseases AT claudiucpopescu treatmentofaxialspondyloarthritispatientswithbiologicdiseasemodifyingantirheumaticdrugsin2022datafromtheromanianregistryofrheumaticdiseases AT elenarezus treatmentofaxialspondyloarthritispatientswithbiologicdiseasemodifyingantirheumaticdrugsin2022datafromtheromanianregistryofrheumaticdiseases AT razvanconstantinionitescu treatmentofaxialspondyloarthritispatientswithbiologicdiseasemodifyingantirheumaticdrugsin2022datafromtheromanianregistryofrheumaticdiseases AT anamariaramazan treatmentofaxialspondyloarthritispatientswithbiologicdiseasemodifyingantirheumaticdrugsin2022datafromtheromanianregistryofrheumaticdiseases AT andreieugenmartin treatmentofaxialspondyloarthritispatientswithbiologicdiseasemodifyingantirheumaticdrugsin2022datafromtheromanianregistryofrheumaticdiseases AT catalincodreanu treatmentofaxialspondyloarthritispatientswithbiologicdiseasemodifyingantirheumaticdrugsin2022datafromtheromanianregistryofrheumaticdiseases |